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Association of Co-Exposure of Antenatal Steroid and Prophylactic
Indomethacin with Spontaneous Intestinal Perforation
Hemasree Kandraju, MD1, Jaideep Kanungo, MD2, Kyong-Soon Lee, MD1,3, Sibasis Daspal, MD4, Mohammad Amin Adie, MD5,
Jon Dorling, MBChB, MD6, Xiang Y. Ye, MSc7, Shoo K. Lee, MBBS, FRCPC, PhD1,7,8, and Prakesh S. Shah, MD, MSc1,7,8,
on behalf of the Canadian Neonatal Network (CNN), and Canadian Preterm Birth Network (CPTBN) Investigators*
Objective To evaluate the association of a combined exposure to antenatal steroids and prophylactic indomethacin with the outcome of spontaneous intestinal perforation (SIP) among neonates born at <26 weeks of gestation or
<750 g birth weight.
Study design We conducted a retrospective study of preterm infants admitted to Canadian Neonatal Network
units between 2010 and 2018. Infants were classified into 2 groups based on receipt of antenatal steroids; the latter
subgrouped as recent (£7 days before birth) or latent (>7 days before birth) exposures. The co-exposure was prophylactic indomethacin. The primary outcome was SIP. Multivariable logistic regression analysis was used to calculate aORs.
Results Among 4720 eligible infants, 4121 (87%) received antenatal steroids and 1045 (22.1%) received prophylactic indomethacin. Among infants exposed to antenatal steroids, those who received prophylactic indomethacin
had higher odds of SIP (aOR 1.61, 95% CI 1.14-2.28) compared with no prophylactic indomethacin. Subgroup analyses revealed recent antenatal steroids exposure with prophylactic indomethacin had higher odds of SIP (aOR
1.67, 95% CI 1.15-2.43), but latent antenatal steroids exposure with prophylactic indomethacin did not (aOR
1.24, 95% CI 0.48-3.21), compared with the respective groups with no prophylactic indomethacin. Among those
not exposed to antenatal steroids, mortality was lower among those who received prophylactic indomethacin
(aOR 0.45, 95% CI 0.28-0.73) compared with no prophylactic indomethacin.
Conclusions In preterm neonates of <26 weeks of gestation or birth weight <750 g, co-exposure of antenatal steroids and prophylactic indomethacin was associated with SIP, especially if antenatal steroids was received within
7 days before birth. Among those unexposed to antenatal steroids, prophylactic indomethacin was associated with
lower odds of mortality. (J Pediatr 2021;235:34-41).

See related article, p 26 and
See editorial, p 18

A

ntenatal steroids are a standard of care for preterm infants to reduce
mortality and intraventricular hemorrhage (IVH).1 Postnatal prophylactic indomethacin has been shown to reduce severe IVH (grades 3
or 4) and patent ductus arteriosus (PDA) in preterm and extremely low birth
weight neonates in both randomized trials and observational studies.2-4 However, several exposures, including postnatal glucocorticoids and indomethacin,
have been associated with spontaneous intestinal perforation (SIP). Indomethacin decreases blood flow to the intestine and may result in direct mucosal
injury amplified by its enterohepatic circulation.5,6 Some studies found that
indomethacin use early in the postnatal period was associated with SIP7-10;
however, a randomized controlled trial of indomethacin prophylaxis did not
show higher rates of gastrointestinal complications linked to its use.4 There
is also conflicting evidence regarding the associations between prophylactic
indomethacin and SIP when used alone or with early feeding.11 Although
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steroids. A case-control trial24 found the risk for SIP was
higher when antenatal betamethasone was given closer to
delivery.
Considering the inconclusive state of the evidence
regarding competing risks and benefits of antenatal steroids and prophylactic indomethacin for SIP and other
important outcomes, our objective was to evaluate the association between antenatal steroids and prophylactic
indomethacin co-exposure and the outcome of SIP
among neonates of <26 weeks of gestation or <750 g
birth weight, and to consider the influence of antenatal
steroids exposure timing.

several neonatal intensive care units (NICUs) have
continued the practice of administering prophylactic indomethacin to preterm or extremely low birth weight neonates to reduce the risk of IVH,12 the potential benefits of
prophylactic indomethacin in preventing severe IVH may
be countered by higher odds of SIP. Both SIP13,14 and severe IVH are associated with significant morbidity, mortality, and neurodevelopmental impairment. The incidence of
SIP is reported to be approximately 5% in infants
<1000 g,15 and the incidence of severe IVH is reported to
be 10%-16% in extremely preterm infants.16-18
Experimental studies reveal that postnatal glucocorticoids
alter ileal tissue growth in the neonate, resulting in mucosal
hyperplasia and concomitant submucosal thinning and
potentially explaining the relationship with SIP.19,20 A secondary analyses from a recent trial revealed that higher
cortisol levels after birth were associated with higher odds
of SIP in infants who received postnatal hydrocortisone.21
Exposure to antenatal steroids and prophylactic indomethacin was postulated to be associated with SIP.22 A previous
study did not find an association between antenatal steroids
and SIP, whether alone or in combination with prophylactic
indomethacin,23 but it lacked data on the timing of antenatal

Methods
We conducted a retrospective cohort study including preterm infants of gestational age of <26 weeks or birth weight
<750 g admitted to NICUs participating in the Canadian
Neonatal Network (CNN) between January 2010 and
December 2018. We excluded infants who had major
congenital anomalies, those who received palliative care at
admission, and those who received postnatal steroids within
14 days of birth. We also excluded infants with missing data

Infants with gestational age <26 weeks or birth weight
<750 g admitted to NICUs in CNN between 2010 and 2018

N = 6622
Total infants excluded: n = 1902
1. Postnatal steroid within 14 days of
birth (n = 1111)
2. Major congenital anomaly (n = 273)
3. Moribund (n = 243)
4. Missing antenatal steroid data (or
timing) (n = 256)
5. Missing indomethacin data (n = 15)
6. Missing date of birth (n = 2)
7. Missing postnatal steroid date (n = 2)

Infants included in
analysis: N = 4720

Did not receive antenatal steroids
n = 599

Received antenatal steroids
n = 4121

Recent steroid
(antenatal steroids ≤7d before
birth)
n = 3287

No prophylactic
indomethacin

n = 2540

Latent steroid
(antenatal steroids >7d before
birth)
n = 834

prophylactic
indomethacin
n = 747

No prophylactic
indomethacin

n = 664

No prophylactic
indomethacin

n = 471

prophylactic
indomethacin
n = 128

prophylactic
indomethacin
n = 170

Figure. Study population.
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on date of birth, timing of antenatal steroids, indomethacin
use, and timing of postnatal steroid (Figure).
Co-exposures
We hypothesized that the timing of exposure to antenatal
steroids may affect the risk of SIP, with exposure more
proximate to birth having the higher risk. To explore this hypothesis, we first divided eligible infants into 2 groups: no
antenatal steroids and antenatal steroids. Based on the timing
of antenatal steroids, the latter group was subdivided into a
“recent” steroid group (complete or partial course of antenatal steroids £7 days before birth) and a “latent” steroid
group (complete or partial course of antenatal steroids
>7 days before birth). All groups were further divided into
2 subgroups based on co-exposure to prophylactic indomethacin or not. The antenatal steroid used by centers in
Canada is betamethasone 12 mg (combination of betamethasone phosphate 6 mg and betamethasone acetate 6 mg).
Complete course of antenatal steroids was defined as 2 doses
of 12 mg of betamethasone given 24 hours apart, and partial
course was defined as receipt of only 1 dose of betamethasone. Prophylactic indomethacin was defined as the use of
indomethacin within the first 24 hours after birth for prevention of IVH and not for treatment of symptomatic PDA. The
dosage of prophylactic indomethacin was 0.1 mg/kg/dose
given intravenously at 24-hour intervals for 3 doses.
Outcomes
Our primary outcome was occurrence of SIP, defined as
radiologic finding of intestinal perforation with absence of
radiological features of intestinal ischemia, such as fixed
dilated bowel loops or pneumatosis intestinalis; or intraoperative surgical report; or histopathologic confirmation of
perforation located in the ileum and on the antimesenteric
border.25 Our secondary outcomes were severe IVH, defined
as IVH with ventricular dilatation or parenchymal hemorrhage; and mortality before discharge. Treatment for PDA
was evaluated as a post-hoc outcome after the results of the
primary analyses were available.
Definitions
Gestational age was defined as the best estimate based on the
date of in vitro fertilization, early ultrasound, last menstrual
period, obstetric estimate, or pediatric estimate, in that hierarchical order. Small for gestational age was defined as birth
weight less than the 10th percentile for gestational age and
sex.26 Treated PDA was defined as therapeutic treatment
with indomethacin, ibuprofen, acetaminophen, or surgical
ligation for closure of PDA.
Data Collection
Data were collected from patient charts at the individual sites
following procedures outlined in the CNN Abstractor’s
Manual.27 The data were entered electronically and transmitted to the central coordinating center at Mount Sinai
Hospital, Toronto. The CNN database has been shown to
36

Volume 235

have high reliability and internal consistency.28 Data on
maternal and infant characteristics, the timing of antenatal
steroids, prophylactic indomethacin (usage within the first
24 hours after birth), and other predisposing factors were
retrieved from the database for analysis. Ethical approval
for this study was obtained from the Research Ethics Board
at Mount Sinai Hospital and the Executive Committee of
the CNN.
Statistical Analyses
The study population was summarized descriptively.
Maternal and infant characteristics were compared between
prophylactic indomethacin exposure groups (prophylactic
indomethacin and no prophylactic indomethacin) for each
antenatal steroids group (none, any, recent, or latent) using
the c2 test for categorical variables and the Student t test or
Wilcoxon rank-sum test, as appropriate, for continuous variables. To examine the associations between outcomes and
exposures, the outcomes were compared between the prophylactic indomethacin exposure groups for each antenatal
steroids group using the c2 test. Multivariable logistic regression models were further applied to determine the effects of
the exposures on the primary and secondary outcomes for
each exposure group, adjusted for potential confounders.
For a post-hoc analysis evaluating the association between
prophylactic indomethacin and treatment for PDA, we
applied similar methods to those described above. Data management and all statistical analyses were performed using SAS
9.4 (SAS Institute Inc). A 2-sided P value of <.05 was considered statistically significant.

Results
During the study period, a total of 6622 infants were
admitted to CNN NICUs, of whom 1902 were excluded
based on the exclusion criteria (Figure). The remaining
4720 infants (71% of total) were included in the analysis
and, of these, 4121 (87%) received antenatal steroids and
1045 (22.1%) received prophylactic indomethacin. Table I
presents comparisons of maternal and infant characteristics
between different exposure groups. Infants who received
prophylactic indomethacin were born at younger
gestational age and had lower birth weights than those who
did not receive prophylactic indomethacin. The percentage
of small for gestational age was less in infants who received
prophylactic indomethacin in all the steroid groups. The
history of receipt of antenatal magnesium sulfate was
higher in infants who were exposed to antenatal steroids
and prophylactic indomethacin compared with those who
were not exposed to antenatal steroids. Table II reports
results from univariate comparisons of outcomes within
each antenatal steroids group between infants who received
prophylactic indomethacin and those who received no
prophylactic indomethacin.
Table III shows results from adjusted analyses comparing
the prophylactic indomethacin vs the no prophylactic
Kandraju et al
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13.5 (23/170)
10.2 (17/167)
66.3 (112/169)*
25 (24, 25)*
709 (116)
50.3 (85/169)
44.1 (75/170)
67.1 (114/170)
15.3 (26/170)*
40.5 (68/168)
60 (102/170)
11.8 (20/170)
23.5 (40/170)

indomethacin group within each antenatal steroids
exposure group. The odds of SIP were higher for infants
who received any antenatal steroids and prophylactic
indomethacin, and especially for those who received
recent antenatal steroids and prophylactic indomethacin,
compared with those in the respective antenatal steroids
groups who did not receive prophylactic indomethacin.
There were no differences in the odds of severe IVH or
mortality before discharge for prophylactic indomethacin
vs no prophylactic indomethacin in any antenatal steroids
group. Among infants who did not receive antenatal
steroids, the odds of mortality were lower in those
exposed to prophylactic indomethacin. In the latent
antenatal steroids group, there were no differences in the
odds of SIP, severe IVH, or mortality according to
prophylactic indomethacin exposure.
In post-hoc analyses, we evaluated whether prophylactic
indomethacin was associated with treatment for PDA. Results are shown in Tables II and III. Prophylactic
indomethacin administration was associated with lower
rates and lower odds of treated PDA among infants who
received recent or latent antenatal steroids, but not for
those who did not receive antenatal steroids.

Discussion

15.3 (113/738)*
6.3 (46/734)
70.5 (514/729)*
24 (24, 25)*
683 (121)*
49.9 (371/744)
49.4 (365/739)
74.8 (559/747)*
11.7 (87/745)*
42.1 (312/741)
50.7 (378/746)*
12.7 (95/747)
5.9 (43/735)
PPROM, preterm pre-labor rupture of membranes; SGA, small for gestational age; SNAP, score for neonatal acute physiology.
*P <.05 for comparison between no prophylactic indomethacin and prophylactic indomethacin groups.

Maternal hypertension, % (n/N)
Maternal diabetes, % (n/N)
Magnesium sulfate, % (n/N)
Gestational age, median (IQR), wk
Birth weight, mean (SD), g
Male, % (n/N)
Apgar <7 at 5 min, % (n/N)
Singleton, % (n/N)
SGA, % (n/N)
SNAP-II score >20, % (n/N)
Cesarean delivery, % (n/N)
Inotropes within 3 d, % (n/N)
PPROM >1 wk, % (n/N)

7.9 (35/440)
5.1 (22/430)
12.8 (56/438)
25 (23, 25)
715 (198)
52.6 (247/470)
64.4 (282/438)
77.9 (367/471)
14.9 (70/470)
45.8 (196/428)
40.8 (192/471)
23.8 (112/471)
2.1 (9/426)

4.8 (6/125)
5.0 (6/119)
14.1 (18/128)
24 (23, 25)*
675 (124)*
42.9 (55/128)
74.8 (86/115)*
75 (96/128)
5.5 (7/128)*
56.4 (71/126)*
38.3 (49/128)
28.9 (37/128)
0.8 (1/121)

21.1 (667/3157)
7.4 (228/3078)
58.4 (1805/3092)
25 (24, 26)
711 (136)
49.4 (1582/3200)
49.8 (1589/3189)
77.1 (2471/3204)
25.1 (803/3203)
39.9 (1252/3135)
61.9 (1979/3199)
15.0 (482/3204)
8.8 (276/3128)

14.9 (136/908)*
6.9 (63/901)
69.7 (626/898)*
24 (24, 25)*
668 (120)*
49.9 (456/913)
48.4 (440/909)
73.4 (673/917)*
12.4 (113/915)*
41.8 (380/909)
52.4 (480/916)
12.5 (115/917)
9.2 (83/905)

21.9 (548/2499)
7.0 (171/2434)
59.6 (1460/2449)
25 (24, 25)
705 (131)
48.8 (1239/2537)
51.6 (1304/2528)
78.9 (2006/2540)
23.8 (605/2539)
39.9 (991/2481)
60.6 (1538/2537)
14.4 (365/2540)
5.5 (136/2478)

18.1 (119/658)
8.9 (57/644)
53.6 (345/643)
25 (25, 26)
733 (152)
51.7 (343/663)
43.1 (285/661)
70.0 (465/664)
29.8 (198/664)
39.9 (261/654)
66.6 (441/662)
17.6 (117/664)
21.5 (140/650)

(n = 170)
(n = 747)
Characteristics

(n = 471)

(n = 128)

(n = 3204)

(n = 917)

(n = 2540)

(n = 664)

Prophylactic
indomethacin
No prophylactic
indomethacin
Prophylactic
indomethacin
No prophylactic
indomethacin
Prophylactic
indomethacin
No prophylactic
indomethacin
Prophylactic
indomethacin
No prophylactic
indomethacin

No steroid

Table I. Maternal and infant baseline characteristics

Any steroid

Recent steroid (antenatal
steroids £7d before birth)

Latent steroid (antenatal
steroids >7d before birth)

August 2021

In this large, population-based study, the overall incidence
of SIP was 4.2% among neonates of <26 weeks of gestational age or <750 g birth weight. Infants exposed to antenatal steroids at any time before birth and co-exposed to
prophylactic indomethacin had higher odds of SIP than
those who did not receive prophylactic indomethacin,
especially if antenatal steroid was received within 7 days
before birth. Infants not exposed to antenatal steroids
and exposed to prophylactic indomethacin had lower
odds of mortality than those who did not receive prophylactic indomethacin. Infants exposed to antenatal steroids
had no differences in the odds of severe IVH or mortality
whether or not they received prophylactic indomethacin
and infants exposed to antenatal steroids more than
7 days before birth had no differences in the odds of
SIP, severe IVH, or mortality whether or not they received
prophylactic indomethacin.
The relationship of antenatal steroids and prophylactic
indomethacin has been explored previously. Using a national dataset, Attridge et al conducted a case-control study
of infants with isolated bowel perforation matched with
controls and observed that infants in the SIP group had
higher rates of exposure to indomethacin alone and coexposure of antenatal steroids and indomethacin.23 However, the authors identified that the combination of antenatal
steroids with indomethacin was not associated with
increased SIP when compared with indomethacin alone.
The timing of antenatal steroids was not available, and
they did not differentiate between the use of indomethacin
for prophylaxis or treatment of PDA. Arnautovic et al24

Association of Co-Exposure of Antenatal Steroid and Prophylactic Indomethacin with Spontaneous Intestinal Perforation
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.74
.46
.61
<.01
3.5 (6/170)
16.6 (28/169)
12.9 (22/170)
36 (60/169)
3.0 (20/660)
14.3 (91/637)
14.5 (96/664)
48 (312/655)
<.01
.14
.81
.02
7 (49/743)
18 (129/726)
20 (147/747)
46 (338/733)
4 (96/2516)
16 (371/2398)
20 (510/2540)
51 (1273/2489)
<.01
.09
.74
.001
6 (55/913)
18 (157/895)
18 (169/917)
44 (398/902)
5 (23/460)
30 (117/392)
43 (204/471)
46 (200/432)

Outcomes

SIP, % (n/N)
Severe IVH, % (n/N)
Mortality, % (n/N)
Treated PDA % (n/N)

Bold text indicates statistically significant differences in the outcome.

P
value
No
prophylactic
indomethacin
(471)

Prophylactic
indomethacin
(128)

4 (116/3176)
15 (462/3035)
19 (606/3204)
50 (1585/3144)

P
value
Prophylactic
indomethacin
(917)
No
prophylactic
indomethacin
(3204)

Any steroid
No steroid

.61
.79
.02
.81

P
Prophylactic
indomethacin
(747)
No
prophylactic
indomethacin
(2540)

Recent steroid
(antenatal steroids
£7d before birth)

Table II. Univariate analyses of outcome rates
38

4 (5/128)
29 (34/119)
32 (41/128)
45 (55/122)

Prophylactic
indomethacin
(170)
No
prophylactic
indomethacin
(664)

Latent steroid (antenatal
steroids >7d before birth)

P value
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studied 57 infants with SIP and matched them with 114 infants without SIP born at <29 weeks of gestational age.
Almost all infants in both groups received prophylactic indomethacin, 43% of SIP cases and 36% of controls were
exposed to maternal indomethacin, and 87% of cases and
94% of controls were exposed to prenatal steroids
(P = .16). However, the authors reported that, among infants
with SIP, the odds of SIP increased by 1% for each 1-hour
decrease in the interval between the last dose of betamethasone and birth. Wadhawan et al10 reported a higher risk of
SIP with indomethacin used for PDA, but not with prophylactic indomethacin. Contrary to our results, they reported
that exposure to antenatal steroids was associated with lower
odds of SIP. In that study, the co-exposure of antenatal steroids and prophylactic indomethacin was not examined
and the timing of antenatal steroids was not reported. The
Trial of Prophylactic Indomethacin in Preterm investigators29 conducted a post-hoc analysis to evaluate whether
antenatal steroids exposure modified the effects of prophylactic indomethacin on death or neurodevelopmental
impairment, PDA, and severe IVH. They reported that antenatal steroids exposure was not associated with statistically
significant heterogeneity for neonatal outcomes or longerterm effects of prophylactic indomethacin. Thus, evidence
supporting or refuting this association between coexposure to antenatal steroids and prophylactic indomethacin with SIP has been tenuous and needs exploration in a
larger database or a randomized trial.
Our observation of higher SIP with antenatal steroids,
especially when antenatal steroids was administered within
7 days before birth, followed by postnatal exposure to prophylactic indomethacin, may be explained by the theory
that the initial insult to the gut from exposure to antenatal
steroids is compounded by the effects of indomethacin. In
animal studies, it was observed that, the loss of nitric oxide
synthase (NOS) in the intestinal smooth muscle via combined inhibition of the neuronal NOS by steroids and endothelial NOS by indomethacin leads to disturbed intestinal
motility and increases vulnerability of the intestine to perforation.30-32 Extensive work on the pharmacokinetics and
pharmacodynamics of antenatal steroids containing betamethasone33 identified that the betamethasone acetate component of the combination, widely used in developed
countries, is released very slowly in circulation, especially
when given intramuscularly, leading to prolonged maternal
and fetal levels for at least 4-6 days. This may explain coexposure having a pronounced effect when exposure to antenatal steroid was recent. Kajantie et al34 found glucocorticoid
bioavailability was elevated in neonates born within 12 hours
after a dose of antenatal steroids, and that this response gradually disappeared over 3 days afterward. This observed duration of action of antenatal steroids lends support to our
observation of higher SIP risk when antenatal steroids exposure was more recent, as there may be inadequate time for the
intestinal mucosa to recover. In a secondary analysis of a
recent multicenter randomized controlled trial including infants <28 weeks of gestational age at birth, Renolleau et al21
Kandraju et al
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Table III. Comparisons of outcome rates between prophylactic indomethacin and no prophylactic indomethacin
groups

No steroid
Outcomes

Unadjusted OR
(95% CI)

SIP
Severe IVH
Mortality
Treated PDA

0.77 (0.29, 2.07)
0.94 (0.60, 1.48)
0.62 (0.41, 0.93)
0.95 (0.64, 1.43)

Recent steroid
(antenatal steroids
£7d before birth)

Any steroid

Latent steroid
(antenatal steroids
>7d before birth)

aOR* (95% CI)

Unadjusted OR
(95% CI)

aOR*
(95% CI)

Unadjusted OR
(95% CI)

aOR*
(95% CI)

Unadjusted OR
(95% CI)

aOR* (95% CI)

0.69 (0.25, 1.88)
0.79 (0.49, 1.27)
0.45 (0.28, 0.73)
0.85 (0.56, 1.30)

1.69 (1.22, 2.35)
1.19 (0.97, 1.45)
0.97 (0.80, 1.17)
0.78 (0.67, 0.90)

1.61 (1.14, 2.28)
1.10 (0.89, 1.35)
0.89 (0.73, 1.09)
0.66 (0.56, 0.77)

1.78 (1.25, 2.54)
1.18 (0.95, 1.47)
0.98 (0.80, 1.20)
0.82 (0.69, 0.96)

1.67 (1.15, 2.43)
1.11 (0.89, 1.40)
0.89 (0.72, 1.10)
0.70 (0.59, 0.84)

1.17 (0.46, 2.96)
1.19 (0.75, 1.89)
0.88 (0.54, 1.45)
0.61 (0.43, 0.86)

1.24 (0.48, 3.21)
1.04 (0.65, 1.67)
0.89 (0.53, 1.47)
0.48 (0.33, 0.69)

ORs are for comparisons of prophylactic indomethacin vs No prophylactic indomethacin within each steroid group (no steroid, any, recent, latent). No prophylactic indomethacin was the reference
group.
For OR (95% CI) values, bold text indicates statistically significant difference in odds.
*ORs were adjusted for the following factors: gestational age, maternal hypertension, receipt of magnesium sulfate, cesarean delivery, small for gestational age, and singleton birth.

measured baseline serum cortisol levels within 24 hours of
life, before administration of hydrocortisone or placebo.
They observed that high baseline cortisol levels were significantly associated with SIP and IVH only in hydrocortisoneexposed infants. The authors proposed that high cortisol
levels immediately after birth may help to identify infants
at higher risk of adverse outcomes produced by hydrocortisone. These findings provide additional evidence supporting
our observation of higher risk for SIP with the combined effect of recent antenatal steroids and prophylactic indomethacin, as susceptibility of the intestine was likely increased due
to higher baseline cortisol levels in the recent antenatal steroids group.
Among infants not exposed to antenatal steroids, we
observed less mortality with exposure to prophylactic indomethacin, which is similar to a report from Jensen et al.35
They noted less mortality with prophylactic indomethacin
in a subgroup of infants with birth weight above the 10th
percentile and among those who did not undergo medical
or surgical therapy for PDA. The authors postulated that
their findings may be due to a protective effect of prophylactic indomethacin against mortality by decreasing symptomatic PDA. However, we found no significant difference in
treated PDA, whether or not they received prophylactic indomethacin. Trial of Prophylactic Indomethacin in Preterm
and other trials found that, although prophylactic indomethacin was associated with reduced incidence of significant
PDA, there was no effect on mortality.3,4,36
Independently, antenatal steroids and prophylactic indomethacin have been shown to reduce the incidence of severe
IVH in several randomized trials and observational
studies.3,4,29,36,37 An expected protective effect of the combination of antenatal steroids and prophylactic indomethacin
against severe IVH (by increasing stability of the cerebral
vasculature and micro vessel maturation in the germinal matrix) was not demonstrated in our study, in any of the steroid
groups, either with or without prophylactic indomethacin.
Our findings may be due to the inclusion of only infants
with the highest risk of IVH (eg, those born at <26 weeks
of gestation or <750 g birth weight), which is a different population from those examined in previous studies.

We found none of the outcomes were different in the latent
steroid group with or without prophylactic indomethacin.
This can be explained by assuming that antenatal steroids
levels gradually dropped after the dose and, as a result, produced no effects on the outcomes. Our findings are consistent with the Cochrane review by Roberts et al,37 who
observed that IVH was not significantly reduced in those
born after 7 days of antenatal corticosteroid therapy.
Key strengths of our study were the use of a populationbased cohort of very high-risk neonates, and meticulous
data collection. We believe this level of detail regarding the
timing of antenatal steroids exposure can help develop a
personalized or targeted approach to guide the use of antenatal steroids and prophylactic indomethacin. However, we
also acknowledge several study limitations. First, we did
not have data on maternal indomethacin, which can increase
the risk of SIP.32,38 However, indomethacin was used as a tocolytic agent in a very small proportion of our patients. Second, it is possible that some neonates in our cohort may have
received postnatal indomethacin or ibuprofen to treat PDA
before developing SIP. We did have data on which patients
received these drugs, but not on the timing of this treatment,
and so could not evaluate the relationship. Third, because the
data were coded in categories rather than age in days, we did
not have data on the exact timing of the receipt of antenatal
steroids or prophylactic indomethacin. More granular data
on antenatal steroids or prophylactic indomethacin timing
could provide more precision regarding the age of exposure
and should be explored in future studies. Fourth, this was a
retrospective study with the inherent potential for residual
confounding. Fifth, different centers participating in CNN
varied in their use of prophylactic indomethacin, and this
may have affected the outcomes. However, we could not fit
a model including site as a random variable because many
sites had zero events and the model did not converge.
Whether or not to use prophylactic indomethacin has been
debated extensively in neonatal practice, and individual NICUs have taken different approaches. Some NICUs use prophylactic indomethacin when their baseline rates of severe
IVH are high, or for select populations. With prophylactic
indomethacin use, the literature has suggested there is a
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trade-off between an increased risk of SIP and decreased risk
of severe IVH. Our findings provide new evidence that infants co-exposed to antenatal steroids and prophylactic indomethacin had higher odds of SIP than those exposed to
antenatal steroids alone, especially if antenatal steroids was
given within the week before birth, without decrease in the
odds of severe IVH or mortality. Further studies are required
to determine whether our findings are replicable.
In summary, among preterm infants born at <26 weeks of
gestational age or <750 g birth weight who were exposed to
antenatal steroids, co-exposure with prophylactic indomethacin was associated with higher odds of SIP, especially when
antenatal steroids exposure was within 7 days before birth,
but not with decreases in the odds of severe IVH or mortality.
We also observed lower odds of mortality among infants not
exposed to antenatal steroids who received prophylactic
indomethacin compared with those who did not receive prophylactic indomethacin. Although further studies will be
needed to confirm or refute our current findings, the associations we identified may support the development and
evaluation of an individualized approach for prophylactic
indomethacin that is based on whether antenatal steroids
was received and at what time. n
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50 Years Ago in THE JOURNAL OF PEDIATRICS
The Importance of Negative Studies in Current Management of Pertussis
in Children
Balagtas R, Nelson K, Levin S, Gotoff S. Treatment of pertussis with pertussis immune globulin. J Pediatr 1971;79:203-8.

A

lthough pertussis vaccine was invented in 1914 and was available as a combined diphtheria–tetanus–pertussis vaccine in 1940, in early 1970 there were ongoing efforts to improve the treatment of exposed individuals who were
not completely immunized. One therapy, pertussis immune globulin, was based on reports of the beneficial effect of
serum or whole blood from convalescent patients. However, there were few controlled trials. In addition, due to issues
of confirming a diagnosis, there were challenges in enrolling patients early in the disease course.
In 1971, Balagtas et al conducted a double-blind, randomized controlled study to assess the effectiveness of pertussis
immune globulin in 74 children who had a clinical diagnosis of pertussis. The immune globulin was administered early
in the paroxysmal stage. The analysis suggested that, compared with controls, the children treated with pertussis immune globulin demonstrated no difference in the course of disease. The outcomes were based on the frequency of
coughing paroxysms, whooping, and vomiting and required suctioning over the next 24 days. These findings were
consistent with published controlled studies at that time. This study is an example of the importance of negative
studies in helping clinicians identify therapies that are not helpful for children. In this way, the study is influential
in how we currently approach our management of pertussis in children who are incompletely immunized.
Today, in general, pertussis vaccination is still the best form of prevention. However, early start of a macrolide is the
optimal treatment choice of active disease as well as prevention of disease in susceptible (eg, non- or incompletely
immunized) exposed individuals.1
Koorosh Nemati, MD
Michael D. Cabana, MD, MPH
Department of Pediatrics
The Children’s Hospital at Montefiore and the Albert Einstein College of Medicine
Bronx, New York

Reference
1. Centers for Disease Control and Prevention. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis:
2005 CDC guidelines. MMWR Recomm Rep 2005;54:1-16.

Association of Co-Exposure of Antenatal Steroid and Prophylactic Indomethacin with Spontaneous Intestinal Perforation

41

THE JOURNAL OF PEDIATRICS



www.jpeds.com

APPENDIX
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Jennifer Toye, MD, and Khalid Aziz, MBBS, Royal Alexandra Hospital, Edmonton, Alberta; Carlos Fajardo, MD, Alberta Children’s Hospital, Calgary, Alberta; Jaya Bodani,
MD, Regina General Hospital, Regina, Saskatchewan; Lannae Strueby, MD, Royal University Hospital, Saskatoon,
Saskatchewan; Mary Seshia, MBChB, and Deepak Louis,
MD, Winnipeg Health Sciences Center, Winnipeg, Manitoba; Ruben Alvaro, MD, St. Boniface General Hospital,
Winnipeg, Manitoba; Amit Mukerji, MD, Hamilton Health
Sciences Center, Hamilton, Ontario; Orlando Da Silva, MD,
MSc, London Health Sciences Center, London, Ontario;
Eugene Ng, MD, Sunnybrook Health Sciences Center, Toronto, Ontario; Brigitte Lemyre, MD, The Ottawa Hospital,
Ottawa, Ontario; Thierry Daboval, MD, Children’s Hospital
of Eastern Ontario, Ottawa, Ontario; Faiza Khurshid, MD,
Kingston General Hospital, Kingston, Ontario; Ermelinda
Pelausa, MD, Jewish General Hospital, Montreal, Quebec;
Keith Barrington, MBChB, Anie Lapoint, MD, and Guillaume Ethier, NNP, H^
opital Sainte-Justine, Montreal,
Quebec; Christine Drolet, MD, and Bruno Piedboeuf,
MD, Center Hospitalier Universitaire de Quebec, Sainte
Foy, Quebec; Martine Claveau, MSc, LLM, NNP, Montreal
Children’s Hospital at McGill University Health Center,
Montreal, Quebec; Marie St-Hilaire, MD, H^
opital
Maisonneuve-Rosemont, Montreal, Quebec; Valerie Bertelle, MD, and Edith Masse, MD, Center Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec; Roderick
Canning, MD, Moncton Hospital, Moncton, New Brunswick; Hala Makary, MD, Dr. Everett Chalmers Hospital,
Fredericton, New Brunswick; Cecil Ojah, MBBS, and Luis
Monterrosa, MD, Saint John Regional Hospital, Saint
John, New Brunswick; Julie Emberley, MD, Janeway Children’s Health and Rehabilitation Center, St. John’s,
Newfoundland; Jehier Afifi, MB BCh, MSc, IWK Health
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Center, Halifax, Nova Scotia; Andrzej Kajetanowicz, MD,
Cape Breton Regional Hospital, Sydney, Nova Scotia.
Canadian Preterm Birth Network Site Investigators
and Affiliations
Wendy Whittle, MD, Mount Sinai Hospital, Toronto, Ontario; Michelle Morais, MD, Hamilton Health Sciences Center, Hamilton, Ontario; Leanne Dahlgren, MD, Children’s
and Women’s Health Center of BC, Vancouver, British
Columbia; Darine El-Chaar, MD, Children’s Hospital of
Eastern Ontario, Ottawa, Ontario; Katherine Theriault,
MD, Center Hospitalier Universitaire de Quebec, Sainte
Foy, Quebec; Annie Ouellet, MD, Center Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec; Kimberly Butt,
MD, Dr. Everett Chalmers Hospital, Fredericton, New
Brunswick; Stephen Wood, MD, Foothills Medical Center,
Calgary, Alberta; Amy Metcalfe, PhD, Foothills Medical Center, University of Calgary, Calgary, Alberta; Candace
O’Quinn, MD, Foothills Medical Center, University of Calgary, Calgary, Alberta; Christy Pylypjuk, MD, Health Sciences Center, Winnipeg, Manitoba; Isabelle Boucoiran,
MSc, MD, H^
opital Sainte-Justine, Montreal, Quebec; Catherine Taillefer, MD, H^
opital Sainte-Justine, Montreal,
Quebec; Joan Crane, MD, Janeway Children’s Health and
Rehabilitation Center, St. John’s, Newfoundland; Haim
Abenhaim, MD, Jewish General Hospital, Montreal, Quebec;
Graeme Smith, MD, Kingston General Hospital, Kingston,
Ontario; Karen Wou, MDCM, McGill University Health
Center, Montreal, Quebec; Sue Chandra, MD, Royal Alexandra Hospital/Stollery Children’s Hospital, Edmonton, Alberta; Jagdeep Ubhi, MD, Royal Columbian Hospital, New
Westminster, British Columbia; George Carson, MD, Regina
General Hospital, Regina, Saskatchewan; Michael Helewa,
MD, St. Boniface General Hospital, Winnipeg, Manitoba;
Ariadna Grigoriu, MD, The Moncton Hospital, Moncton,
New Brunswick; Rob Gratton, MD, McGill University Health
Center, Montreal, Quebec; James Andrews, MD, Saint John
Regional Hospital, St. John, New Brunswick; Nir Melamed,
MD, Sunnybrook Health Sciences Center, Toronto, Ontario;
Jason Burrows, MD, Surrey Memorial Hospital, Surrey,
British Columbia; Fatima Taboun, MD, Windsor Regional
Hospital, Windsor, Ontario; Lara Wesson, MD, Royal University Hospital, Saskatoon, Saskatchewan; Erin MacLellan,
MD, Cape Breton Regional Hospital, Mira Road, Nova
Scotia; Hayley Boss, MD, Victoria General Hospital, Victoria,
British Columbia; Vicky Allen, MD, IWK Health Center,
Halifax, Nova Scotia.
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